- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06332755
Studie zur Bewertung von LB-LR1109 zur Behandlung solider Tumoren (LB-LR1109)
Eine erste offene, multizentrische Dosiseskalationsstudie der Phase 1 am Menschen zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik und Pharmakodynamik von LB-LR1109 zur Behandlung fortgeschrittener oder metastasierter solider Tumoren
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and/or metastatic NSCLC.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- NEXT Oncology
-
Kontakt:
- Alexander Spirra
- Telefonnummer: 703-783-4508
- E-Mail: alexander.spira@usoncology.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
-
Age ≥18 years old at the time of signing the ICF.
-
(Phase 1a only) Participants must have 1 of the following histologically confirmed advanced or metastatic solid tumors with measurable or non-measurable disease as determined by RECIST v1.1,
- NSCLC, HNSCC, RCC, urothelial carcinoma, or malignant melanoma.
-
(Phase 1a only) Participants who have metastatic disease which has progressed during or after approved standard therapies or are intolerant to approved therapies, or for which the participant refuses or is ineligible for standard therapy.
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
-
Life expectancy ≥12 weeks.
-
Participants with adequate organ function
-
No potential for childbearing or agree to use adequate contraception
-
Ability to understand the study purpose and procedures and have the willingness to sign a written informed consent document.
-
(Phase 1b only ) Must have histologically confirmed advanced or metastatic NSCLC without actionable genomic alteration that have approved therapies in the location where the participant's live and with measurable disease as determined by RECIST v1.1
Key Exclusion Criteria:
- Clinically significant cardiac disease or cardiac failure.
- Untreated or unstable brain or central nervous system (CNS) metastases or Leptomeningeal disease
- Participants with any concurrent active malignancies
- Has received prior therapy targeting LILRB or immunoglobulin-like transcript pathway.
- History of life-threatening toxicity related to prior immune therapy
- Has not recovered to ≤ Grade 1 or baseline from AEs and/or complications from prior surgical intervention or any anti-cancer treatment before starting study treatment
- Participants must not have an active, known, or suspected autoimmune disease.
- Evidence of active infection requiring IV antibiotic treatment ≤7 days prior to initiation of study treatment therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry).
- Pregnant or lactating or expecting to conceive a child during the study or within 6 months after the last dose of study intervention.
- Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study intervention and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
- (Phase 1b only) Participants who were previously exposed to atezolizumab
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Phase 1a: Dosis-Eskalation / LB-LR1109 Monotherapie
|
intravenous administration |
|
Experimental: Phase 1b: Dosis-Eskalation / LB-LR1109 in Kombination mit Atezolizumab
|
intravenous administration |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLC
Zeitfenster: through study completion, an average of 1year
|
Number of participants with dose-limiting toxicities (DLTs) |
through study completion, an average of 1year
|
|
Phase 1a: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as monotherapy / Phase 1b: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as combination therapy with atezolizumab
Zeitfenster: through study completion, an average of 1year
|
Incidence, severity (assessed by NCI CTCAE v5.0), and causality of AEs |
through study completion, an average of 1year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase 1a / 1b: Preliminary efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Zeitfenster: through study completion, an average of 1year
|
ORR(overall response rate) assessed by RECIST v1.1 (%) |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Antitumor efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Zeitfenster: through study completion, an average of 1year
|
PFS(Progression free survival) |
through study completion, an average of 1year
|
|
Phase 1a/1b: Antitumor efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Zeitfenster: through study completion, an average of 1year
|
OS (Overall survival) (months) |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Pharmacokinetic profile of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Zeitfenster: through study completion, an average of 1year
|
Cmax (Maximum serum drug concentration) |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Characterize PK of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Zeitfenster: through study completion, an average of 1year
|
Area under the concentration-time curve (AUC) 0-last |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Immunogenicity of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Zeitfenster: through study completion, an average of 1year
|
Number and percentage of participants with ADAs |
through study completion, an average of 1year
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Männliche Urogenitalerkrankungen
- Nierenerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Erkrankungen der Atemwege
- Neubildungen nach histologischem Typ
- Lungenkrankheit
- Kopf-Hals-Neubildungen
- Neubildungen, Drüsen und Epithelien
- Adenokarzinom
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Lungentumoren
- Hautkrankheiten
- Urologische Neubildungen
- Karzinom
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Nierentumoren
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Neuroendokrine Tumoren
- Nävi und Melanome
- Hauttumoren
- Karzinom, Plattenepithel
- Haut- und Bindegewebserkrankungen
- Plattenepithelkarzinom von Kopf und Hals
- Karzinom, Nierenzelle
- Karzinom, nicht-kleinzellige Lunge
- Melanom
- Karzinom, Übergangszelle
- Atezolizumab
Andere Studien-ID-Nummern
- LG-LRCL001
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .